Skip to main content
SpringerLink
Log in

Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Despite the efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depression, a significant number of patients show partial or no remission of symptoms. Some evidence suggests that psychostimulant augmentation may be helpful in treating patients with residual symptoms of depression. The efficacy of modafinil in augmenting SSRIs in depressed patients with residual fatigue or excessive daytime sleepiness has yet to be systematically investigated. In a series of 25 patients with major depressive disorder, according to the criteria of theDiagnostic and Statistical Manual of Mental Disorders, 4th edition, who showed significant residual symptoms after an adequate SSRI trial (12 wk) and who were evaluated according to the Fatigue Severity Scale (FSS), subjects with scores ≥4 were given open-label modafinil augmentation for a minimum of an additional 6 wk. Treatment response was assessed prospectively with the FSS, the Epworth Sleepiness Scale (ESS), and the Hamilton Rating Scale for Depression (HAM-D) during the first visit and at the second and sixth weeks. Twenty-one of 25 patients in this series who were treated with modafinil and SSRIs completed the 6-wk augmentation trial. At end-point assessment, all patients showed significant improvement in fatigue and sleepiness in FSS and ESS scores, as well as in HAM-D scores (P< .01). In the second week, 29.4% of patients had a HAM-D score < 7, which was defined as remission; this rate was 64.7% in the sixth week. The rate of patients whose HAM-D score dropped by more than 50%, defined as responders to treatment, was 41.1% and 76.4% in the second and sixth weeks, respectively. Results of this preliminary, open-label trial suggest that modafinil may be effective in augmenting ongoing SSRI treatment for a portion of patients with major depression who have residual fatigue and sleepiness. Larger, placebo-controlled trials appear warranted to investigate the clinical efficacy and tolerability of modafinil augmentation of SSRI treatment in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Angst J, Gamma A, Gastpar M, et al. Gender differences in depression. Epidemiological findings from the European DEPRES I and II studies.Eur Arch Psychiatry Clin Neurosci. 2002;252:201–209.

    Article  PubMed  CAS  Google Scholar 

  2. Nerenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine.J Clin Psychiatry. 1999;60:221–225.

    Article  Google Scholar 

  3. Addington AM, Gallo JJ, Ford DE, Eaton WW. Epidemiology of unexplained fatigue and major depression in the community: the Baltimore ECA follow-up, 1981–1994.Psychol Med. 2001;31:1037–1044.

    Article  PubMed  CAS  Google Scholar 

  4. Feighner JP, Herbstein J, Damlouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.J Clin Psychiatry. 1985;46:206–209.

    PubMed  CAS  Google Scholar 

  5. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group.Neurology. 2000;54:1166–1175.

    Google Scholar 

  6. Arnulf I. Excessive daytime sleepiness in parkinsonism.Sleep Med Rev. 2005;9:185–200.

    Article  PubMed  Google Scholar 

  7. Stankoff B, Waubant E, Confavreux C, et al, the French Modafinil Study Group. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.Neurology. 2005;12:1139–1143.

    Google Scholar 

  8. Lundt L. Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study.J Affect Disord. 2004;81:173–178.

    Article  PubMed  CAS  Google Scholar 

  9. Schwartz TL, Azhar N, Cole K, et al. An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy.J Clin Psychiatry. 2004;65:1223–1237.

    PubMed  Google Scholar 

  10. Wesensten NJ, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balken TJ. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine.Psychopharmacology. 2002;159:238–247.

    Article  PubMed  CAS  Google Scholar 

  11. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.J Clin Psychiatry. 2005;66:85–93.

    Article  PubMed  CAS  Google Scholar 

  12. Holder G, Brand S, Hatzinger M, Holsboer-Trachsler E. Reduction of daytime sleepiness in a depressive patient during adjunct treatment with modafinil.J Psychiatr Res. 2002;36:49–52.

    Article  PubMed  Google Scholar 

  13. Menza MA, Kaufmann KR, Castellanos AM. Modafinil augmentation of antidepressant treatment in depression.J Clin Psychiatry. 2000;61:378–381.

    Article  PubMed  CAS  Google Scholar 

  14. Markovitz PJ, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy.J Clin Psychopharmacol. 2003;23:207–209.

    Article  PubMed  Google Scholar 

  15. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus.Arch Neurol. 1989;46:1121–1123.

    PubMed  CAS  Google Scholar 

  16. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale.Sleep. 1991;14:540–545.

    PubMed  CAS  Google Scholar 

  17. Nasr S. Modafinil as adjunctive therapy in depressed outpatients.Ann Clin Psychiatry. 2004;16:133–138.

    PubMed  Google Scholar 

  18. Kaufman KR, Menza MA, Fitzsimmons A. Modafinil monotherapy in depression.Eur Psychiatry. 2002;17:167–169.

    Article  PubMed  Google Scholar 

  19. Scammell TE, Estabrooke IV, McCarthy MT. Hypothalamic arousal regions are activated during modafinil induced wakefulness.J Neurosci. 2000;20:8620–8628.

    PubMed  CAS  Google Scholar 

  20. DeBattista C, Lembke A, Solvason H, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression.J Clin Psychopharmacol. 2004;24:87–90.

    Article  PubMed  CAS  Google Scholar 

  21. Ninan PT, Hassman HA, Glass SJ, McManus FC. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.J Clin Psychiatry. 2004;65:414–420.

    Article  PubMed  CAS  Google Scholar 

  22. Chouinard G, Saxena B, Belanger MC, et al. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.J Affect Disord. 1999;54:39–48.

    Article  PubMed  CAS  Google Scholar 

  23. DeBattista C, Doghramji K, Menza MA. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.J Clin Psychiatry. 2003;64:1057–1064.

    Article  PubMed  CAS  Google Scholar 

  24. Robertson P, DeCory HH, Madan A, Parkinson A. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.Drug Metab Dispos. 2000;28:664–671.

    PubMed  CAS  Google Scholar 

  25. Vorspan F, Warot D, Consoli A, Cohen D, Mazet P. Mania in a boy treated with modafinil for narcolepsy.Am J Psychiatry. 2005;16:813–814.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine Department of Psychiatry, Zonguldak Karaelmas University, 67600, Kozlu/Zonguldak, Turkey

    Numan Konuk MD (Asst Prof), Nuray Atasoy MD (Asst Prof), Levent Atik MD (Asst Prof) & Ömer Akay MD (Research Asst)

Authors
  1. Numan Konuk MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nuray Atasoy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Levent Atik MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ömer Akay MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Konuk, N., Atasoy, N., Atik, L. et al. Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors. Adv Therapy 23, 646–654 (2006). https://doi.org/10.1007/BF02850053

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850053

Keywords

Search

Navigation